More Execs Speak Out Over Risks Of UK Voluntary Pricing Scheme For Life Sciences
In 2022, a total of five companies chose to exit the UK’s voluntary scheme that manages branded medicines spending. The departure of two big firms – AbbVie and Lilly – is seen as a deliberate tactic to send a clear signal to government that the scheme is not working for industry and is jeopardizing investment and access to medicines in the UK.
You may also be interested in...
Novo Nordisk has been hit by a serious sanction in the UK after having been found to effectively pay pharmacists to promote Saxenda.
Novo Nordisk has been given a two-year suspension from membership of the Association of the British Pharmaceutical Industry for breaching the association’s code of practice.
The UK government is standing its ground on this year’s hike in the statutory pricing scheme rebate, despite industry worries about the impact on companies’ investment decisions.